Jun 9, 20211 min
$DRRX +0% DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL). source
$ATOS -28% Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated. source
$AVDL +1% Avadel Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy at SLEEP 2021. source
$OMER +1% OMEROS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1 CLINICAL TRIAL OF OMS906. source
$ARNA +2% ARENA PHARMACEUTICALS ANNOUNCES ORPHAN DRUG DESIGNATION FOR ETRASIMOD FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EOE). source
$SCYX -1% SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections. source
$INZY +1% Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency. source
$ADMS -1% FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021. source
Posted by DV